Literature DB >> 15342452

Plasma vitamin D metabolites and risk of colorectal cancer in women.

Diane Feskanich1, Jing Ma, Charles S Fuchs, Gregory J Kirkner, Susan E Hankinson, Bruce W Hollis, Edward L Giovannucci.   

Abstract

OBJECTIVE: Experimental evidence suggests that 1,25-dihydroxyvitamin D and its precursor, 25-hydroxyvitamin D [25(OH)D], may aid in the prevention of colorectal cancer. We therefore examined risk in relation to plasma concentrations of these vitamin D metabolites.
METHODS: In a nested case-control study among women in the Nurses' Health Study, we identified 193 colorectal cancer cases, ages 46 to 78 years, diagnosed up to 11 years after blood collection. Two controls were matched per case on year of birth and month of blood draw. Odds ratios (OR) for risk of colorectal cancer were calculated using conditional logistic regression adjusted for body mass index, physical activity, smoking, family history, use of hormone replacement therapy, aspirin use, and dietary intakes.
RESULTS: We found a significant inverse linear association between plasma 25(OH)D and risk of colorectal cancer (P = 0.02). Among women in the highest quintile, the OR (95% confidence interval) was 0.53 (0.27-1.04). This inverse association remained strong when limited to women > or =60 years at blood collection (P = 0.006) but was not apparent among the younger women (P = 0.70). Benefit from higher 25(OH)D concentrations was observed for cancers at the distal colon and rectum (P = 0.02) but was not evident for those at the proximal colon (P = 0.81). In contrast to 25(OH)D, we did not observe an association between 1,25-dihydroxyvitamin D and colorectal cancer, although risk was elevated among the women in the highest quintile if they were also in the lower half of the 25(OH)D distribution (OR, 2.52; 95% confidence interval, 1.04-6.11).
CONCLUSION: From these results and supporting evidence from previous studies, we conclude that higher plasma levels of 25(OH)D are associated with a lower risk of colorectal cancer in older women, particularly for cancers at the distal colon and rectum.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15342452

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  120 in total

1.  Blood 25-hydroxyvitamin D3 concentrations and incident sporadic colorectal adenoma risk: a pooled case-control study.

Authors:  Veronika Fedirko; Roberd M Bostick; Michael Goodman; W Dana Flanders; Myron D Gross
Journal:  Am J Epidemiol       Date:  2010-07-22       Impact factor: 4.897

Review 2.  Time course of risk factors in cancer etiology and progression.

Authors:  Esther K Wei; Kathleen Y Wolin; Graham A Colditz
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

3.  Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Authors:  Stephanie J Weinstein; Mark P Purdue; Stephanie A Smith-Warner; Alison M Mondul; Amanda Black; Jiyoung Ahn; Wen-Yi Huang; Ronald L Horst; William Kopp; Helen Rager; Regina G Ziegler; Demetrius Albanes
Journal:  Int J Cancer       Date:  2014-09-02       Impact factor: 7.396

4.  Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells.

Authors:  Erik J Tokar; Mukta M Webber
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

5.  New perspectives on vitamin D sources in Germany based on a novel mathematical bottom-up model of 25(OH)D serum concentrations.

Authors:  Jonathan Brown; Anita Ignatius; Michael Amling; Florian Barvencik
Journal:  Eur J Nutr       Date:  2012-12-11       Impact factor: 5.614

6.  Determinants of serum 25 hydroxyvitamin D levels in a nationwide cohort of blacks and non-Hispanic whites.

Authors:  Jacqueline Chan; Karen Jaceldo-Siegl; Gary E Fraser
Journal:  Cancer Causes Control       Date:  2009-12-11       Impact factor: 2.506

7.  Chemoprevention for colorectal neoplasia.

Authors:  Alyssa D Fajardo; Bruce W Robb
Journal:  Clin Colon Rectal Surg       Date:  2008-11

8.  Vitamin D receptor and retinoid X receptor α status and vitamin D insufficiency in models of murine colitis.

Authors:  Rebecca W Knackstedt; Vondina R Moseley; Shaoli Sun; Michael J Wargovich
Journal:  Cancer Prev Res (Phila)       Date:  2013-04-12

9.  Genetic variation in the vitamin D receptor (VDR) and the vitamin D-binding protein (GC) and risk for colorectal cancer: results from the Colon Cancer Family Registry.

Authors:  Jenny N Poynter; Elizabeth T Jacobs; Jane C Figueiredo; Won H Lee; David V Conti; Peter T Campbell; A Joan Levine; Paul Limburg; Loic Le Marchand; Michelle Cotterchio; Polly A Newcomb; John D Potter; Mark A Jenkins; John L Hopper; David J Duggan; John A Baron; Robert W Haile
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01-19       Impact factor: 4.254

10.  Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.

Authors:  D Michal Freedman; Shih-Chen Chang; Roni T Falk; Mark P Purdue; Wen-Yi Huang; Catherine A McCarty; Bruce W Hollis; Barry I Graubard; Christine D Berg; Regina G Ziegler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04-01       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.